Cost Effectiveness of Influenza Vaccination in Older Adults

  title={Cost Effectiveness of Influenza Vaccination in Older Adults},
  author={Anthony T. Newall and Heath A. Kelly and Stuart Harsley and Paul A. Scuffham},
AbstractSeveral recent studies have assessed the benefits of extending influenza vaccination programmes, which are currently targeted primarily at those aged over 65 years, to those aged 50–64 years. We identified and reviewed all costeffectiveness studies of influenza vaccination in those aged 50–64 years published before July 2008. While the studies suggest that vaccination in this age-group is likely to be cost effective, these results were dependent on several key assumptions. The estimates… 

Economic Evaluations of Childhood Influenza Vaccination

A literature search of economic evaluations of influenza vaccination in those aged ≤18 years revealed 20 relevant articles, which were reviewed and generally favourable for vaccination, but often applied a wider perspective than the reference case for economic evaluations used in many countries.

Uncertainty and variability in influenza cost‐effectiveness models

  • A. NewallP. Scuffham
  • Medicine, Political Science
    Australian and New Zealand journal of public health
  • 2011
It is not reasonable to use this type of variability, as opposed to other forms of uncertainty, to draw conclusions that influenza vaccination programs should not be funded, and further research should be funded to help inform uncertain key parameters in influenza models.

Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies

Given the importance of knowing the impact of changes to influenza policy, such complexities need careful treatment using tools such as population-based trial designs, meta-analyses, time-series analyses and transmission dynamic models.

Economic value of influenza vaccination

The vaccination was demonstrated to be cost-effective or cost-saving in almost all studies, independently by the perspective and the type of analysis.

Issues in the Economic Evaluation of Influenza Vaccination by Injection of Healthy Working Adults in the US

Based on their assumptions, the reviewed papers collectively appear to support the economic benefits of influenza vaccination of healthy adults, but the underlying assumptions, methods and parameter estimates themselves warrant further research to confirm they are accurate, reliable and appropriate to economic evaluation purposes.

Implementing an Influenza Vaccination Programme for Adults Aged ≥ 65 Years in Poland

Implementing a vaccination programme in Poland in which influenza vaccination would be fully reimbursed by the NFZ for people aged ≥65 years would be a very cost-effective strategy, below the 2009 yearly gross domestic product (GDP) per capita.

Net Costs Due to Seasonal Influenza Vaccination — United States, 2005–2009

Averted costs vary significantly per season; however, in seasons where the averted burden of deaths is high in the older age group, averted productivity losses due to premature death tilt overall seasonal results towards savings.



Economic Evaluations of Influenza Vaccination in Healthy Working-Age Adults

It is suggested that influenza vaccination in the healthy, working adult would be a cost-effective health intervention, at least from the perspective of an employer, partly because of the disparity among economic studies in their methods of estimating costs and measuring effects.

Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.

Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.

  • K. Nichol
  • Medicine, Political Science
    Archives of internal medicine
  • 2001
Influenza vaccination of healthy working adults on average is cost saving, and these findings support a strategy of routine, annual vaccination for this group, especially when vaccination occurs in efficient and low-cost sites.

The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.

  • S. AballéaJ. Chancellor M. Weinstein
  • Medicine, Political Science
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2007
An economic evaluation of lowering the age limit for routine influenza vaccination to 50 years in Brazil, France, Germany, and Italy finds that extension to people more than 50 years of age is likely to be cost-effective in all four countries studied.

Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.

Mortality benefits of influenza vaccination in elderly people.